Biosimilar Antibodies

Nuvustotug is a human monoclonal antibody of the IgG1κ subtype that specifically targets TNFRSF4. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

The Anti-CD28 Antibody (9.3) is a chimeric mouse IgG2a antibody designed to specifically target human CD28. This antibody serves as a crucial tool for the modulation and study of CD28 signaling pathways, which are vital in T-cell activation and immune response. For accurate experimental control, it is recommended to use Mouse IgG2a kappa as an isotype control. This antibody is suitable for a variety of immunological applications, including flow cytometry, immunoprecipitation, and other assays requiring precise CD28 targeting.

Solnerstotug is a human monoclonal antibody of the IgG1κ subtype that specifically targets V-set immunoregulatory receptor (VSIR). For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is designed for use in research studies focused on immune regulation and VSIR-mediated pathways.

Concizumab, an IgG4 subtype monoclonal antibody, targets the Kunitz-type protease inhibitor 2 (KPI-2) structural domain of tissue factor pathway inhibitor (TFPI). By binding to this domain, Concizumab effectively inhibits the interaction between TFPI and the Factor Xa (FXa) active site. This antibody is particularly useful for research in hemophilia, providing insights into novel therapeutic interventions targeting coagulation pathways.

Stapokibart (CM310) is a humanized monoclonal antibody specifically designed to target IL-4Rα, effectively inhibiting the binding of cytokines IL-4 and IL-13 to their co-receptor subunit IL-4Rα. This antibody demonstrates cross-species reactivity, interacting with IL-4Rα in humans, cynomolgus monkeys, and rats, making it a versatile tool for diverse biological research settings.

Obertamig is a humanized monoclonal antibody engineered to target CD3E and HLA-G. It features modifications in the CH2-CH3 regions and is composed of a hybrid structure that includes half of an immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv). This design enhances its specificity and efficacy in binding to its designated antigens, making it an ideal candidate for research in immune response modulation and therapeutic applications targeting these molecules.

VIS-410 is a fully human monoclonal antibody of the IgG1 subclass that specifically targets the influenza A virus. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is designed for use in research studies aimed at understanding and potentially mitigating the impact of influenza A infections.

Volagidemab is a monoclonal antibody designed to act as an antagonist to the glucagon receptor (GCGR). This antibody is specifically developed for use in research focused on Type 1 Diabetes (T1D), providing a critical tool for investigating the role of GCGR in glucose regulation and diabetic pathology.

Efungumab is a monoclonal antibody characterized by its potent antifungal properties. This antibody specifically targets and binds to Heat Shock Protein 90 (HSP 90), a critical component in fungal cell viability. By binding to this protein, Efungumab inhibits a necessary conformational change, thereby compromising fungal cell survival. This mechanism of action makes Efungumab an invaluable tool for research focused on invasive candidiasis (IC), providing insights into fungal pathogenesis and potential therapeutic interventions.

Sontuzumab (AS1402) is a humanized IgG1κ monoclonal antibody that exhibits high specificity for the MUC1 antigen, targeting the extracellular peptide sequence PDTR with a dissociation constant (Kd) of approximately 1 nM. This antibody is primarily utilized in the research of breast cancer, providing a valuable tool for the study of MUC1-related oncogenic pathways and potential therapeutic interventions.

Voxalatamab (JNJ-63898081) is a bispecific IgG4 monoclonal antibody designed to target both PSMA (Prostate-Specific Membrane Antigen) and CD3. This antibody exhibits anticancer activity and is specifically developed for research in prostate cancer. Voxalatamab facilitates the engagement of T-cells to PSMA-expressing tumor cells, offering a strategic approach for investigating immune-mediated cancer cell eradication.

Anti-CD98 monoclonal antibody (Clone KHK2898) specifically targets CD98, a protein implicated in amino acid transport and integrin signaling. This antibody is ideal for research applications aiming to elucidate the role of CD98 in cellular processes such as nutrient uptake, cell adhesion, and tumor progression.

Omburtamab is a monoclonal antibody targeting CD276, also known as B7-H3, which is a member of the B7/CD28 immunoglobulin superfamily. CD276 is prominently expressed in a variety of solid human tumors. This antibody has the capability to specifically bind to tumor tissues, making it a valuable tool for research in cancer biology and therapeutic development across multiple cancer types.

hT84.66-M5A is a humanized IgG1 monoclonal antibody specifically designed to target the carcinoembryonic antigen (CEA), a widely studied tumor marker implicated in various types of cancers. This antibody mimics the natural immune response against tumor cells expressing CEA, making it an essential tool for research in oncology and cancer diagnostics. The recommended isotype control for hT84.66-M5A is Human IgG1 kappa, which serves as a critical baseline to validate the specificity and ensure the accuracy of immunoassays involving this antibody.

Bapotulimab (BAY-1905254) is a fully humanized IgG2 monoclonal antibody designed to specifically target the immunoglobulin-like domain containing receptor 2 (ILDR2). This antibody exhibits potent antitumor activity and immunosuppressive properties, making it a valuable tool for research in cancer immunotherapy and immune regulation.

Tixagevimab (AZD8895) is a human monoclonal antibody designed to target the receptor binding domain (RBD) of SARS-CoV-2. It effectively neutralizes the virus by binding to the RBD as well as the S-glycoprotein ectodomain, thereby inhibiting the S-glycoprotein-mediated attachment to the host cell receptor. This antibody is pivotal for research focused on the mechanisms of viral entry and the development of therapeutic strategies against SARS-CoV-2.

Zifibancimig is a monoclonal antibody of the IgG1κ isotype, designed to target and neutralize both VEGFA (Vascular Endothelial Growth Factor A) and ANGPT2 (Angiopoietin-2). This dual specificity makes it a valuable tool for investigating the complex interplay between these two critical angiogenic factors in various pathological conditions. Zifibancimig is utilized primarily in research focused on angiogenesis, tumor growth, and vascular diseases.

Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody designed to selectively bind to the B cell maturation antigen (BCMA) on the surface of multiple myeloma (MM) cells and the CD3 receptor on T cells. This dual binding facilitates the targeted destruction of MM cells by directing and activating T cells to recognize and eliminate BCMA-expressing tumor cells. Linvoseltamab is primarily utilized in research focused on relapsed or refractory multiple myeloma (RRMM), providing a valuable tool for investigating novel therapeutic strategies in this challenging clinical area.

Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody designed to specifically target and neutralize the calcitonin gene-related peptide (CGRP) ligand. This antibody is utilized extensively in research focused on migraine and cluster headaches, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these conditions.

Mupadolimab (CPI-006) is a humanized IgG1κ monoclonal antibody designed to selectively target CD73 with modified FcγR binding properties to reduce effector function. This antibody is engineered to activate CD73-positive B cells, playing a crucial role in modulating immune responses. Its unique mechanism and specificity make it an invaluable tool for research focused on immunology and oncology, particularly in studies exploring the regulation of the immune checkpoint pathways.

Tomaralimab (OPN-305) is a humanized IgG4 monoclonal antibody targeting Toll-like receptor 2 (TLR2). This antibody is designed for investigational use in the study of Myelodysplastic Syndromes (MDS), offering potential insights into the role of TLR2 in the pathogenesis of this condition.

Ravulizumab (ALXN1210) is a humanized monoclonal antibody engineered to bind with high affinity to the human complement protein C5. This antibody is pivotal in the inhibition of the terminal complement cascade, a key component in immune response and inflammation. Ravulizumab is primarily utilized in the investigation of diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis, offering a significant tool for understanding the pathophysiology and therapeutic interventions of these conditions.

Iparomlimab is a monoclonal IgG4κ antibody that targets the human programmed death-1 receptor (PD-1, also known as CD279 or PDCD1). This antibody is engineered to bind specifically to the PD-1 receptor, a critical molecule involved in the negative regulation of immune responses and a key therapeutic target in oncology. Iparomlimab is composed of a γ4-chain and a κ-chain of the human monoclonal antibody PSB103, linked by a disulfide bond to form a stable dimer. This biologic is primarily utilized in research focused on cancer immunotherapy, investigating the modulation of immune checkpoints that are pivotal in tumor immune evasion.

Mogamulizumab (KW-0761) is a recombinant monoclonal antibody that targets CC chemokine receptor 4 (CCR4). This antibody facilitates the elimination of tumor cells through antibody-dependent cellular cytotoxicity (ADCC), a critical mechanism for immune-mediated tumor cell eradication. Mogamulizumab is primarily utilized in the investigation of various cancers, including adult T-cell leukemia/lymphoma (ATLL) and cutaneous T-cell lymphoma (CTCL), providing a valuable tool for research in oncology and immunotherapy.

Anselamimab (CAEL-101) is a humanized IgG1-κ monoclonal antibody designed to specifically target serum amyloid A1 (SAA1) amyloid fibrils. This antibody binds with high affinity to the SAA1 amyloid fibrils, a key pathological component in amyloidosis disorders, thereby offering potential for therapeutic intervention and disease-modifying effects in amyloid-related diseases. Anselamimab is utilized primarily in research focused on the pathogenesis and treatment of amyloidosis, making it a valuable tool for both basic research and clinical development studies.

Divozilimab (BCD-132) is a humanized monoclonal antibody specifically targeting CD20, a cell surface protein primarily expressed on B lymphocytes. This antibody is utilized extensively in the study of multiple sclerosis, aiding in the exploration of B-cell mediated pathogenesis and potential therapeutic interventions.

Tarlatamab (AMG-757) is a first-in-class, half-life extended (HLE) bispecific T-cell engager (BiTE) antibody designed for targeted immuno-oncology applications. This therapeutic antibody specifically targets delta-like ligand 3 (DLL3), a protein predominantly expressed in small-cell lung cancer (SCLC) cells, with minimal expression in healthy tissues. Tarlatamab exhibits high binding affinities with dissociation constants (K_Ds) of 0.64 nM for human DLL3 and 0.50 nM for nonhuman primate (NHP) DLL3. Additionally, it shows binding affinities of 14.9 nM and 12 nM for human and NHP CD3, respectively. The selective targeting of DLL3 and the engagement of CD3, a critical component of the T-cell receptor complex, make Tarlatamab a promising candidate for the study and potential treatment of SCLC.

Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody designed to selectively bind with high affinity to colony-stimulating factor 1 receptor (CSF-1R). This antibody is primarily utilized in research focused on chronic graft versus host disease (cGVHD) and various neoplastic diseases, providing a valuable tool for studies aimed at elucidating the role of CSF-1R in these complex conditions.

Comekibart is a humanized IgG4κ monoclonal antibody specifically targeting the IL4 receptor (IL4R). For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as the isotype control. This specificity and isotype matching ensure accurate and reliable results in research applications focusing on the modulation and study of IL4R-mediated signaling pathways.

Dafsolimab (SPV-T3a) is a murine monoclonal antibody of the IgG2a subclass, targeting the CD3 antigen on T cells. This antibody functions by modulating and activating the CD3/T cell receptor complex, subsequently inducing T cell death. Dafsolimab is primarily utilized in research focused on understanding and treating graft-versus-host disease (GVHD), offering significant insights into T cell behaviors and immune responses in this condition.

The Anti-CD3 Antibody (OKT-3) is a chimeric mouse monoclonal antibody of the IgG2a, κ isotype, specifically designed to target human CD3. For optimal experimental control, it is recommended to use the Mouse IgG2a kappa Isotype Control. This antibody is pivotal for studies involving T-cell activation and response, making it an essential tool for immunological research.

The Anti-ROBO1 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the Roundabout Guidance Receptor 1 (ROBO1), playing a crucial role in neural development and axonal guidance. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

The Anti-CD4 Antibody (Hu5A8) is a humanized IgG4 monoclonal antibody designed to specifically target CD4, a critical molecule involved in the immune response and a key marker on helper T cells. For rigorous experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is optimal for research applications seeking to elucidate the role of CD4 in immune function and pathology.

Velinotamig is a bispecific antibody of the H-γ1_L-κ/H-γ1_L-κ type, designed to target CD3E and TNFRSF17. This antibody facilitates dual engagement, directing T-cell mediated immune responses specifically towards cells expressing TNFRSF17. It is utilized primarily in research focusing on the mechanisms of immune modulation and potential therapeutic strategies for diseases characterized by overexpression of TNFRSF17.

CR-8020 is a human IgG1 monoclonal antibody designed to specifically target the H3N2 subtype of influenza A virus. This antibody recognizes and binds to the hemagglutinin (HA) protein of H3N2 strains, demonstrating potent inhibitory concentrations (IC50) of 3.36 nM and 0.06 nM against A/Brisbane/10/2007 and A/Wyoming/3/2003 strains, respectively. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. CR-8020 serves as a valuable tool for research focused on the immunological response to H3N2 infections and the development of therapeutic strategies against influenza A.

MEDI-2045 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting IL-4Ra/CD124. This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, and exhibits a predicted molecular weight of approximately 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Benufutamab (GEN1029) is an agonistic antibody targeting death receptor 5 (DR5), designed to selectively initiate apoptosis in tumor cells. This biologic is composed of two non-competing, DR5-specific IgG1 antibodies, each engineered with an E430G mutation in the Fc domain to enhance its therapeutic efficacy. Benufutamab demonstrates significant antitumor activity, making it a valuable tool for research in cancer therapy and apoptosis mechanisms.

Vorsetuzumab, a recombinant human anti-CD70 antibody, targets the CD70 antigen expressed on various tumor cells. This antibody has been shown to enhance macrophage-mediated phagocytosis of renal carcinoma cells and exhibit inhibitory effects on Burkitt’s lymphoma. Vorsetuzumab holds significant potential for therapeutic applications in oncology, particularly in the treatment of renal carcinoma and Burkitt’s lymphoma, by modulating immune responses against tumor cells.

Ciduvectamig is a human IgG4 κ monoclonal antibody targeting CD3E and TMEFF2. For experimental rigor, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for specificity in binding to both CD3E, a key component in T-cell receptor signaling, and TMEFF2, which plays a role in cellular differentiation and proliferation. It is ideal for research applications investigating immune response modulation and cancer biology.

Relfovetmab is a monoclonal antibody that targets nerve growth factor (NGF). This antibody is specifically designed to bind and inhibit NGF, a key molecule involved in the regulation of pain and inflammation. Relfovetmab's mechanism of action makes it a valuable tool for research into pain management and the biological pathways of inflammation.

Blosozumab (LY2541546) is a monoclonal antibody that targets human sclerostin (SOST), functioning as an inhibitor. This antibody promotes bone formation while concurrently decreasing bone resorption, making it a valuable tool in osteoporosis research. Blosozumab is specifically designed to elucidate the pathways and potential therapeutic effects related to bone density regulation and osteoporotic condition management.

Nisfevitug is a human IgG1 κ monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control.

The Anti-FZD7 Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the Frizzled-7 (FZD7) receptor, a member of the Frizzled family of G protein-coupled receptors involved in the Wnt signaling pathway. The antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focused on the study of Wnt signaling and its role in developmental processes and diseases.

Misitatug is a chimeric antibody of the IgG1κ isotype, specifically designed to target mesothelin (MSLN). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody designed to specifically target TIGIT (T cell immune receptor with Ig domain and ITIM domains). TIGIT serves as an inhibitory immune checkpoint that plays a critical role in immune regulation by promoting NK cell depletion and diminishing cytokine secretion through its interaction with CD155. This antibody has the capability to inhibit effector T cell functions and enhance the regulation of T regulatory cells, contributing to its immunosuppressive effects. Dargistotug is pivotal in studies focused on immune checkpoint blockade and the modulation of immune responses in various diseases.

REGN-7257 is a humanized monoclonal antibody designed to specifically target IL2RG, effectively inhibiting the signaling pathways of all γ-c cytokines. This antibody is particularly useful in research focused on aplastic anemia. For experimental control purposes, the recommended isotype control is Human IgG4 kappa.

The Anti-TSPAN8 Antibody is derived from human origin and produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the tetraspanin 8 (TSPAN8) protein. It is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for a variety of research applications focusing on the role of TSPAN8 in cellular processes and disease mechanisms.

Canakinumab (ACZ885) is a recombinant human monoclonal antibody that specifically targets and neutralizes interleukin-1 beta (IL-1β). Demonstrating potent inhibitory activity, canakinumab exhibits half-maximal inhibitory concentrations (IC50) of 43.6 pM for human IL-1β and 40.8 pM for marmoset IL-1β. Its primary mechanism involves the interruption of IL-1β signaling, effectively reducing inflammatory responses associated with autoimmune disorders. This antibody is pivotal for research focused on the pathophysiology and potential therapeutic interventions for inflammation-driven diseases.

Cabotamig is a monoclonal antibody that targets both CD3E and CDH17. This dual-specificity allows for potential applications in modulating immune responses and investigating cellular adhesion processes in cancer research. Cabotamig is designed for use in various experimental settings, including flow cytometry, western blotting, and immunohistochemistry, to study the role of these proteins in immune cell function and tumor biology.